CancerDrs

Lung Cancer clinical trials in New York

97 actively recruiting lung cancer trials at 46 sites across New York.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in New York:
  • Wilmot Cancer Center at Batavia — Batavia, New York
  • Northwell Health Imbert Cancer Center — Bay Shore, New York
  • Sands Cancer Center — Canandaigua, New York
  • Memorial Sloan Kettering Commack — Commack, New York
  • Noyes Memorial Hospital/Myers Cancer Center — Dansville, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in New York:
  • Roswell Park Cancer Institute — Buffalo, New York
  • Montefiore Medical Center-Einstein Campus — The Bronx, New York
  • Montefiore Medical Center-Weiler Hospital — The Bronx, New York
  • Montefiore Medical Center - Moses Campus — The Bronx, New York
  • James J Peters VA Medical Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in New York:
  • New York Oncology Hematology - Albany Medical Center — Albany, New York
  • Local Institution - Unk077 — Rhinebeck, New York
  • Montefiore Medical Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in New York:
  • Maimonides Cancer Center — Brooklyn, New York
  • Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
  • Laura and Isaac Perlmutter Cancer Center — New York, New York
  • Manhattan Eye, Ear and Throat Hospital — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in New York:
  • Clinical Study Site — Glen Falls, New York
  • Clinical Study Site — Harrison, New York
  • Clinical Study Site — New York, New York
  • Clinical Study Site — Syracuse, New York
  • Clinical Study Site — Uniondale, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…

Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in New York:
  • Mount Sinai — New York, New York
  • Memorial Sloan Kettering — New York, New York
  • SUNY Upstate Medical University — Syracuse, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in New York:
  • Research Site — Stony Brook, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in New York:
  • NYU Langone Hospital - Brooklyn — Brooklyn, New York
  • Memorial Sloan Kettering Commack — Commack, New York
  • Memorial Sloan Kettering Westchester — Harrison, New York
  • NYU Langone Hospital - Long Island — Mineola, New York
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…

Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in New York:
  • Research Site — East Syracuse, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen
NCT ID: NCT07005128
Sites in New York:
  • New York Oncology Hematology PC — Albany, New York
  • Hematology Oncology Association of Central New York — East Syracuse, New York
  • New York Cancer and Blood Specialists — Shirley, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in New York:
  • Roswell Park Cancer Institute ( Site 0184) — Buffalo, New York
  • Hematology-Oncology Associates of CNY ( Site 0164) — East Syracuse, New York
  • The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216) — New York, New York
  • Icahn School of Medicine at Mount Sinai ( Site 0116) — New York, New York
  • Memorial Sloan Kettering Cancer Center ( Site 0137) — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in New York:
  • Local Institution - 0356 — Hawthorne, New York
  • Veterans Affairs New York Harbor Healthcare System — New York, New York
  • Local Institution - 0380 — Northport, New York
  • University of Rochester Medical Center — Rochester, New York
  • SUNY Upstate Medical University — Syracuse, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in New York:
  • Weill Cornell Medicine (Adults only) — New York, New York
  • Columbia University Medical Center (Adults and Pediatrics) — New York, New York
  • Memorial Sloan Kettering Cancer Center (Adults and Pediatrics) — New York, New York
  • Montefiore Medical Center (Adults only) — The Bronx, New York
  • Montefiore Medical Center (Pediatrics only) — The Bronx, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in New York:
  • Research Site — Brooklyn, New York
  • Research Site — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…

Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in New York:
  • North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists — New York, New York
  • University of Stony Brook — Stony Brook, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in New York:
  • Clinical Research Alliance — Westbury, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and ef…

Sponsor: AbbVie
NCT ID: NCT06236438
Sites in New York:
  • Stony Brook Cancer Center /ID# 261954 — Stony Brook, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in New York:
  • New York Oncology Hematology, P.C. ( Site 0132) — Albany, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in New York:
  • New York Oncology Hematology, P.C. ( Site 0119) — Albany, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (…

Sponsor: Roswell Park Cancer Institute
NCT ID: NCT06563388
Sites in New York:
  • Roswell Park Comprehensive Cancer Center — Buffalo, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in New York:
  • Arnot Ogden Medical Center/Falck Cancer Center — Elmira, New York
  • University of Rochester — Rochester, New York
  • Montefiore Medical Center-Einstein Campus — The Bronx, New York
  • Montefiore Medical Center - Moses Campus — The Bronx, New York
  • James J Peters VA Medical Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT06568939
Sites in New York:
  • Montefiore Medical Center - Einstein Campus /ID# 277169 — The Bronx, New York
  • Clinical Research Alliance - Westbury /ID# 270455 — Westbury, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care trea…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05198830
Sites in New York:
  • Montefiore Medical Center-Einstein Campus — The Bronx, New York
  • Montefiore Medical Center - Moses Campus — The Bronx, New York
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…

Sponsor: Synthekine
NCT ID: NCT05098132
Sites in New York:
  • Northwell Health — Lake Success, New York
  • NYU Langone Health — New York, New York
  • Columbia University Irving Medical Center — New York, New York
  • Memorial Sloan-Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the effic…

Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT06773910
Sites in New York:
  • White Plains Hospital Physician Associates — White Plains, New York
View on ClinicalTrials.gov →

Showing 25 of 97 trials with sites in New York. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07